Ozempic and Wegovy: New Vision Loss Warning Raises Questions About GLP-1 Safety
Users of popular weight-loss and diabetes medications Ozempic and Wegovy have been warned about a rare but serious potential side effect: sudden vision loss. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued an alert on February 5, 2026, regarding a possible link between semaglutide – the active ingredient in these drugs – and non-arteritic anterior ischemic optic neuropathy (NAION).
What is NAION and Why is it Concerning?
NAION occurs when blood flow to the optic nerve is disrupted, leading to sudden, painless vision loss, often described as blurring or cloudiness, typically in one eye. While extremely rare, the MHRA’s warning highlights the importance of awareness among both patients and healthcare professionals. The agency has received three reports of NAION in patients taking semaglutide over the past five years, given an estimated 10.2 million packs distributed.
Which Medications are Affected?
The warning applies to all semaglutide-based medications, including:
- Ozempic: Prescribed for type 2 diabetes.
- Rybelsus: Too used for type 2 diabetes.
- Wegovy: Indicated for weight management and cardiovascular risk reduction in overweight or obese patients.
Recent Safety Concerns and the Rise of GLP-1s
This isn’t the first safety concern raised regarding GLP-1 receptor agonists like semaglutide. Last week, the MHRA also warned about a potential link between these drugs and pancreatitis, a potentially life-threatening inflammation of the pancreas. The agency reported receiving 1,296 reports of pancreatitis associated with these medications in recent years.
The increasing popularity of these drugs, particularly for weight loss, has led to a surge in demand. Approximately two million people in the UK are estimated to be using weight-loss injections. Some patients have switched from Mounjaro (tirzepatide) to Wegovy following a price increase for Mounjaro last September.
What Should Patients Do?
The MHRA advises anyone taking semaglutide who experiences sudden vision changes, such as impairment or rapid worsening of vision in one or both eyes, to seek immediate medical attention at an eye casualty department or A&E. Patients are also encouraged to report any suspected side effects through the MHRA’s Yellow Card scheme.
Understanding the Risk: How Common is NAION with Semaglutide?
While the MHRA stresses the risk is incredibly small, studies suggest NAION may affect up to one in 10,000 people taking semaglutide. Dr. Alison Cave, MHRA’s Chief Safety Officer, emphasized that patient safety remains the agency’s top priority and that they continuously monitor the safety and efficacy of all licensed medicines.
Future Trends and the GLP-1 Landscape
The recent safety alerts surrounding semaglutide and other GLP-1 receptor agonists are likely to prompt increased scrutiny of these medications. Expect to see:
- Enhanced Monitoring: Healthcare providers may implement more rigorous monitoring of patients taking GLP-1s, including baseline and periodic eye exams.
- Refined Patient Selection: More careful patient selection criteria may be developed to identify individuals who may be at higher risk of adverse effects.
- Further Research: Increased investment in research to better understand the long-term safety profile of GLP-1s and to identify potential biomarkers for predicting adverse events.
- Diversification of Weight Loss Options: The emergence of alternative weight loss therapies, including new medications and non-pharmacological interventions, to provide patients with more choices.
Did you know?
The MHRA’s Yellow Card scheme allows patients and healthcare professionals to report suspected side effects to aid monitor the safety of medicines.
FAQ
Q: What are the symptoms of NAION?
A: Sudden, painless vision loss, blurring, or cloudiness in one or both eyes.
Q: Should I stop taking Ozempic or Wegovy if I experience vision changes?
A: No, but seek immediate medical attention and report the symptoms to your doctor and the MHRA.
Q: How common is NAION?
A: NAION is a rare condition, and the risk associated with semaglutide is considered very small, affecting up to one in 10,000 users.
Q: What is the MHRA’s role in medication safety?
A: The MHRA is the UK’s regulator for medicines, vaccines, and medical devices, responsible for monitoring their safety and efficacy.
Pro Tip: Always discuss any new medications or changes in your health with your healthcare provider.
Stay informed about the latest developments in GLP-1 safety and explore our other articles on weight management and diabetes. Share your thoughts and experiences in the comments below!
